NASDAQ:ALEC - Alector Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.67
  • Forecasted Upside: 93.04 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$17.44
▼ -0.49 (-2.73%)
1 month | 3 months | 12 months
Get New Alector Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALEC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$33.67
▲ +93.04% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Alector in the last 3 months. The average price target is $33.67, with a high forecast of $41.00 and a low forecast of $31.00. The average price target represents a 93.04% upside from the last price of $17.44.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Alector.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021Bank of AmericaInitiated CoverageBuy$35.00High
i
11/11/2020Smith Barney CitigroupLower Price Target$40.00 ➝ $31.00Low
i
7/29/2020BarclaysLower Price TargetOverweight$36.00 ➝ $32.00High
i
6/24/2020HC WainwrightInitiated CoverageBuy$41.00Low
i
Rating by A. Fein at HC Wainwright
6/4/2020Morgan StanleyBoost Price TargetOverweight$29.00 ➝ $31.00High
i
4/28/2020The Goldman Sachs GroupInitiated CoverageBuy$32.00Medium
i
4/15/2020Morgan StanleyBoost Price TargetOverweight$27.00 ➝ $29.00High
i
3/5/2020CitigroupInitiated CoverageBuyLow
i
2/27/2020BarclaysInitiated CoverageOverweightHigh
i
2/18/2020Stifel NicolausInitiated CoverageBuyHigh
i
12/16/2019CowenReiterated RatingBuyMedium
i
12/8/2019CowenReiterated RatingBuyHigh
i
11/27/2019BTIG ResearchInitiated CoverageBuy$28.00N/A
i
Rating by Thomas Shrader at BTIG Research
11/21/2019BTIG ResearchInitiated CoverageBuy$28.00Low
i
11/12/2019CowenReiterated RatingBuyLow
i
7/17/2019CowenReiterated RatingBuyHigh
i
5/13/2019CowenReiterated RatingBuyHigh
i
3/4/2019CowenInitiated CoverageOutperformHigh
i
3/4/2019SVB LeerinkInitiated CoverageOutperformHigh
i
3/4/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$27.00Low
i
3/4/2019BarclaysInitiated CoverageOverweight$27.00Low
i
3/4/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$26.00Low
i
(Data available from 1/20/2016 forward)
Alector logo
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $17.44
$17.24
$18.10

50 Day Range

MA: $15.37
$13.66
$17.93

52 Week Range

Now: $17.44
$9.12
$35.93

Volume

385,930 shs

Average Volume

471,523 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Alector?

The following Wall Street research analysts have issued stock ratings on Alector in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., HC Wainwright, Morgan Stanley, Smith Barney Citigroup, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.

What is the current price target for Alector?

6 Wall Street analysts have set twelve-month price targets for Alector in the last year. Their average twelve-month price target is $33.67, suggesting a possible upside of 92.5%. HC Wainwright has the highest price target set, predicting ALEC will reach $41.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $31.00 for Alector in the next year.

What is the current consensus analyst rating for Alector?

Alector currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALEC will outperform the market and that investors should add to their positions of Alector.

What other companies compete with Alector?

How do I contact Alector's investor relations team?

Alector's physical mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 415-231-5660 and its investor relations email address is ir@alector.com. The official website for Alector is www.alector.com.